Oral anticoagulant therapy in atrial fibrillation older patients with previous bleeding

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Direct oral anticoagulants (DOACs) are standard for thromboembolic risk reduction in atrial fibrillation (AF).
• Bleeding risk assessment is crucial for AF patients on oral anticoagulant therapy (OAT).
• Managing OAT after a bleeding event presents clinical challenges, particularly in older adults.

Purpose of the Study:

• To address the unmet need for guidance on managing antithrombotic therapy post-bleeding in AF patients.
• To offer a clinical perspective on restarting or continuing OAT after a bleeding event in older AF patients.

Main Methods:

• This paper provides a clinical perspective, synthesizing current knowledge.
• It discusses the complexities of OAT management following bleeding events.
• It focuses on older patients with atrial fibrillation.

Main Results:

• Major bleeding significantly increases short- and long-term mortality in AF patients.
• Even minor bleeding can lead to treatment disruption and has prognostic importance.
• Decisions regarding OAT initiation or re-initiation after bleeding are often contentious.

Conclusions:

• There is a critical need for evidence-based guidelines for managing antithrombotic therapy after bleeding in AF.
• This perspective aims to inform clinical decision-making while awaiting further data.
• Managing bleeding risk and thromboembolic events requires careful consideration in older AF patients.